These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 27353467

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant Staphylococcus aureus Strains.
    Abdelhady W, Bayer AS, Gonzales R, Li L, Xiong YQ.
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872064
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis.
    Ruggero MA, Peaper DR, Topal JE.
    Infect Dis (Lond); 2015 Jun; 47(6):379-84. PubMed ID: 25746601
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.
    McMullen AR, Lainhart W, Wallace MA, Shupe A, Burnham CD.
    Eur J Clin Microbiol Infect Dis; 2019 Dec; 38(12):2323-2330. PubMed ID: 31446513
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
    Mendes RE, Moet GJ, Janechek MJ, Jones RN.
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2704-6. PubMed ID: 20385851
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.
    Kosowska-Shick K, Clark C, Pankuch GA, McGhee P, Dewasse B, Beachel L, Appelbaum PC.
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4217-24. PubMed ID: 19620338
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States.
    Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN.
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1811-4. PubMed ID: 25561335
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
    Miró JM, García-de-la-Mària C, Armero Y, de-Lazzari E, Soy D, Moreno A, del Rio A, Almela M, Mestres CA, Gatell JM, Jiménez-de-Anta MT, Marco F, Hospital Clínic Experimental Endocarditis Study Group.
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2373-7. PubMed ID: 17485502
    [Abstract] [Full Text] [Related]

  • 14. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates.
    Rehm SJ, Boucher H, Levine D, Campion M, Eisenstein BI, Vigliani GA, Corey GR, Abrutyn E.
    J Antimicrob Chemother; 2008 Dec; 62(6):1413-21. PubMed ID: 18782781
    [Abstract] [Full Text] [Related]

  • 15. Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.
    Roch M, Varela MC, Taglialegna A, Rose WE, Rosato AE.
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914961
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin.
    Marconescu P, Graviss EA, Musher DM.
    Scand J Infect Dis; 2012 Aug; 44(8):620-2. PubMed ID: 22668202
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ, Barber KE, Ireland CE, Rybak MJ.
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [Abstract] [Full Text] [Related]

  • 19. The Combination of Daptomycin and Fosfomycin Has Synergistic, Potent, and Rapid Bactericidal Activity against Methicillin-Resistant Staphylococcus aureus in a Rabbit Model of Experimental Endocarditis.
    García-de-la-Mària C, Gasch O, García-Gonzalez J, Soy D, Shaw E, Ambrosioni J, Almela M, Pericàs JM, Tellez A, Falces C, Hernandez-Meneses M, Sandoval E, Quintana E, Vidal B, Tolosana JM, Fuster D, Llopis J, Pujol M, Moreno A, Marco F, Miró JM.
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610194
    [Abstract] [Full Text] [Related]

  • 20. A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections.
    Chan C, Hardin TC, Smart JI.
    Future Microbiol; 2015 Jun; 10(8):1325-38. PubMed ID: 26083676
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.